Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / KIF1A

KIF1A

Basics

Aliases:
This biomarker is also known as:
  • UNC104,
  • HUnc-104,
  • MRD9,
  • Kinesin, Heavy Chain, Member 1A, Homolog Of Mouse,
  • SPG30,
  • HSN2C,
  • ATSV,
  • Axonal Transport Of Synaptic Vesicles,
  • C2orf20,
  • Kinesin Family Member 1A,
  • Microtubule-Based Motor KIF1A,
  • Kinesin-Like Protein KIF1A,
  • Axonal Transporter Of Synaptic Vesicles,
  • Chromosome 2 Open Reading Frame 20,
  • Unc-104- And KIF1A-Related Protein,
  • Tmp_locus_27,
  • Spastic Paraplegia 30 (Autosomal Recessive),

View in BioMuta

Description…

From NCBI Entrez Gene: The protein encoded by this gene is a member of the kinesin family and functions as an anterograde motor protein that transports membranous organelles along axonal microtubules. Mutations at this locus have been associated with spastic paraplegia-30 and hereditary sensory neuropathy IIC. Alternatively spliced transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Apr 2012]

Attributes

QA State: Curated
Type: Gene
Short Name:
HGNC Name: KIF1A

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Head & neck, NOS

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

KIF1A is one of eight genes on a panel of differentially methylated genes from normal and OSCC clinical samples from patients with heterogenous risk profiles chosen for further validation.  The eight genes are: HOXA9, NID2, GATA4, KIF1A, EDNRB, MCAM, DCC, and CALCA.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.